Biomarker Partnering Terms and Agreements, Worldwide, 2014 to 2020 - Provides Access to Headline, Upfront, Milestone and Royalty Data

DUBLIN, May 14, 2020 /PRNewswire/ -- The "Global Biomarker Partnering Terms and Agreements 2014-2020: Deal trends, players and financials" report has been added to's offering.

This report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the world's leading healthcare companies.

    --  In-depth understanding of biomarker deal trends since 2014
    --  Access to headline, upfront, milestone and royalty data
    --  Analysis of the structure of biomarker agreements with numerous real
        life case studies
    --  Detailed access to actual biomarker contracts enter into by the leading
        fifty bigpharma companies
    --  Access to most active biomarker dealmakers since 2014
    --  Insight into the terms included in a biomarker agreement, together with
        real world clause examples
    --  Understand the key deal terms companies have agreed in previous deals
    --  Undertake due diligence to assess suitability of your proposed deal
        terms for partner companies

The report provides a detailed understanding and analysis of how and why companies enter Biomarker partnering deals and also includes software technologies. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Biomarker agreements announced in the healthcare sectors. The report takes readers through the comprehensive biomarker deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering biomarker partnering deals.

The report presents average financial deal terms values for biomarker deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the biomarker partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This - Chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 450 online deals records of actual biomarker deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Analyzing actual contract agreements allows assessment of the following:

    --  What are the precise biomarker rights granted or optioned?
    --  What is actually granted by the agreement to the partner company?
    --  What exclusivity is granted?
    --  What is the payment structure for the deal?
    --  How are sales and payments audited?
    --  What is the deal term?
    --  How are the key terms of the agreement defined?
    --  How are IPRs handled and owned?
    --  Who is responsible for commercialization?
    --  Who is responsible for development, supply, and manufacture?
    --  How is confidentiality and publication managed?
    --  How are disputes to be resolved?
    --  Under what conditions can the deal be terminated?
    --  What happens when there is a change of ownership?
    --  What sublicensing and subcontracting provisions have been agreed?
    --  Which boilerplate clauses does the company insist upon?
    --  Which boilerplate clauses appear to differ from partner to partner or
        deal type to deal type?
    --  Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

    --  4D Pharma
    --  23andMe
    --  A*STAR Agency for Science
    --  Technology and Research
    --  A*STAR Bioprocessing Technology Institute
    --  Abbott Laboratories
    --  Abbvie
    --  Abcodia
    --  Abramson Cancer Center
    --  Academic Medical Center
    --  Accelerate Diagnostics
    --  Accu Reference Medical Laboratory
    --  AC Immune
    --  Acumen Pharmaceuticals
    --  Adaptive Biotechnologies
    --  Adarza BioSystems
    --  ADC Therapeutics
    --  Aelan Cell Technologies
    --  Aerocrine
    --  AFFiRiS
    --  Affymetrix
    --  Age Labs
    --  Agendia
    --  Air Force Research Laboratory
    --  AIT Laboratories
    --  Akers Biosciences
    --  Akili Interactive Labs
    --  Albert Einstein College of Medicine
    --  Alector
    --  Alion Pharmaceuticals
    --  Almac Diagnostics
    --  ALS Association
    --  ALS Finding a Cure Foundation
    --  Alzeca Biosciences
    --  Alzheimer's Association
    --  Alzheimer's Drug Discovery Foundation
    --  Alzheimers Research UK
    --  Amarantus BioSciences
    --  Amarna Therapeutics
    --  Ambiopharm
    --  American Association for Cancer Research
    --  American Association of Neuromuscular & Electrodiagnostic Medicine
    --  American Diabetes Association
    --  Amgen
    --  AMRA
    --  Anavex Life Sciences
    --  Apogenix
    --  Applied DNA Sciences
    --  Arbor Biotechnologies
    --  Arcis Biotechnology
    --  Arcus Biosciences
    --  AroCell
    --  Arrow Diagnostics
    --  Artialis
    --  Ascenion
    --  Association for Frontotemporal Degeneration
    --  Astellas Pharma
    --  Asterand Bioscience
    --  Asthma UK
    --  AstraZeneca
    --  Astute Medical
    --  Asuragen
    --  Australian Imaging
    --  Biomarker & Lifestyle Flagship Study of Ageing (AIBL)
    --  Austrian Institute of Technology
    --  Autifony Therapeutics
    --  Avera Heart Hospital of South Dakota
    --  Aviana Molecular Technologies
    --  Ayasdi
    --  AyoxxA Biosystems
    --  Banyan Biomarkers
    --  Baxter International
    --  Bayer
    --  Bayer Healthcare
    --  Baylor College of Medicine
    --  Berg
    --  Bertin Pharma
    --  Beth Israel Deaconess Medical Center
    --  BGI Tech Solutions
    --  Bill and Melinda Gates Foundation
    --  Bio-Techne
    --  BioArctic Neuroscience
    --  Biocartis
    --  Biocept
    --  Biodesix
    --  BioDiscovery
    --  Biogen
    --  Biognosys
    --  BioMarker Strategies
    --  Biomedical Catalyst Fund (UK)
    --  bioMerieux
    --  BiomX
    --  BioPorto
    --  Biopsy Sciences
    --  Biothera
    --  BioTheranostics
    --  BioVendor
    --  Bird Foundation
    --  Blackfynn
    --  BlackThorn Therapeutics
    --  Blinktbi
    --  BluePen Biomarkers
    --  Blueprint Medicines
    --  Boehringer Ingelheim
    --  Bonnie J. Addario Lung Cancer Foundation
    --  Brain Biomarker Solutions in Gothenburg
    --  BrainScope
    --  Breath Diagnostics
    --  Brigham and Women's Hospital
    --  Bristol-Myers Squibb
    --  Broad Institute
    --  Buck Institute for Age Research
    --  C2N Diagnostics
    --  Cachet Pharma
    --  California Stem Cell
    --  Cambridge Epigenetix
    --  Cambridge Isotope Laboratories
    --  CANbridge Life Sciences
    --  Cancer Genetics
    --  Cancer Immunotherapy Trials Network
    --  Cancer Research Institute
    --  Cancer Research UK
    --  Caprion Biosciences
    --  Caprion Proteomics
    --  Caris Life Sciences
    --  Carmentix
    --  Carolinas Medical Center (CMC)
    --  Case Western Reserve University
    --  CASI Pharmaceuticals
    --  Catalyn Medical Technologies
    --  Catholic University Leuven
    --  CBD Solutions
    --  Cedars-Sinai Medical Center
    --  Celgene
    --  Cellgen Diagnostics
    --  Celmatix
    --  Celsee
    --  Celsius Therapeutics
    --  Cenix BioScience
    --  Center for Biomarker Research in Medicine
    --  Center for Human Immunology
    --  Autoimmunity and Inflammation
    --  Centers for Disease Control and Prevention
    --  Centre for Drug Research and Development (CDRD)
    --  Centre for Imaging Technology Commercialization
    --  Centre Hospital University - Bordeaux
    --  Centre Leon Berard
    --  Centre National de la Recherche Scientifique
    --  Certis
    --  Cerveau Technologies
    --  CHDI Foundation
    --  Chembio Diagnostics
    --  Children's Hospital Boston
    --  Children's Medical Research Institute
    --  Children's Research Institute
    --  Children's Hospital Colorado
    --  Christian Doppler Research Association
    --  Cincinnati Children's Hospital Medical Center
    --  Circulogene
    --  Cleveland Clinic
    --  Cleveland HeartLab
    --  Clinical Genomics
    --  Cloud Pharmaceuticals
    --  Cognition Therapeutics
    --  Cohen Veterans Bioscience
    --  Columbia University
    --  COPD Foundation
    --  Cornell University
    --  Covance
    --  CRC Health
    --  Critical Diagnostics
    --  Crohn's and Colitis Foundation of America
    --  Crossbeta Biosciences
    --  CSIRO
    --  Curetis
    --  Curie-Cancer
    --  Cypher Genomics
    --  Cytox
    --  Daiichi Sankyo
    --  Dako
    --  Dana-Farber Cancer Institute
    --  Danish Center for Strategic Research into Type 2 Diabetes
    --  Defense Advanced Research Projects Agency
    --  Definiens
    --  Department of Defense
    --  Department of Veterans Affairs

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets